Citadel Advisors
PMVP icon

Citadel Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Citadel Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Buy
84,100
+66,400
+375% +$84.4K ﹤0.01% 11984
2025
Q4 		$22.1K Buy
+17,700
New +$23.7K ﹤0.01% 12315
2025
Q2 		– Sell
-1,700
Closed -$1.85K – 14506
2025
Q1 		$1.85K Buy
1,700
+1,300
+325% +$1.76K ﹤0.01% 14091
2024
Q4 		$604 Sell
400
-2,600
-87% -$4.12K ﹤0.01% 14297
2024
Q3 		$4.47K Buy
3,000
+2,600
+650% +$4.02K ﹤0.01% 13563
2024
Q2 		$648 Sell
400
-1,500
-79% -$2.71K ﹤0.01% 13943
2024
Q1 		$3.23K Sell
1,900
-4,600
-71% -$8.59K ﹤0.01% 13929
2023
Q4 		$20.1K Sell
6,500
-7,100
-52% -$18.8K ﹤0.01% 12610
2023
Q3 		$83.5K Buy
13,600
+11,900
+700% +$81.8K ﹤0.01% 11114
2023
Q2 		$10.6K Buy
1,700
+1,400
+467% +$7.34K ﹤0.01% 13191
2023
Q1 		$1.43K Sell
300
-8,100
-96% -$57K ﹤0.01% 14301
2022
Q4 		$73.1K Buy
+8,400
New +$89.5K ﹤0.01% 11650
2022
Q3 		– Sell
-98,100
Closed -$1.4M – 13362
2022
Q2 		$1.4M Buy
98,100
+56,600
+136% +$824K ﹤0.01% 6270
2022
Q1 		$864K Buy
+41,500
New +$732K ﹤0.01% 8038

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors's PMVP Position: Q1 2026 in Review

Citadel Advisors reduced its PMV Pharmaceuticals (PMVP) stake by 62% in Q1 2026, selling an estimated $93.5K and leaving 45,048 shares worth $55.9K. The position accounts for ﹤0.01% of the portfolio, ranked #12361.

Citadel Advisors first reported a position in PMVP in Q3 2020 and has held it in 23 quarters since. The position peaked at $20.1M in Q2 2022. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

  • Citadel Advisors held 45,048 shares of PMV Pharmaceuticals worth $55.9K as of Q1 2026.
  • Citadel Advisors sold 73,545 PMV Pharmaceuticals shares in Q1 2026, an estimated $93.5K.
  • PMV Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12361 holding.
  • Citadel Advisors first reported a position in PMV Pharmaceuticals in Q3 2020 and has held it in 23 quarters since.
  • Citadel Advisors's PMV Pharmaceuticals position peaked at $20.1M in Q2 2022.
  • 69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.